The Newsroom

Investigations  /  09.24.2020

Investigation of NextCure, Inc.

You Have Legal Options

NextCure, Inc. (NXTC) Accused of Misleading Shareholders  

During the class period, defendants misled investors regarding the efficacy of and objective responses observed in patients treated with NC318 from the Company’s Phase 1 Clinical Trial.  Specifically, on November 5, 2019, NextCure made positive statements regarding its Phase 1 Clinical Trial in connection with the 34th Annual Meeting of Society for Immunotherapy of Cancer, reporting a disease control rate of 71% while committing to present results for the 43 patients dosed with NC318.  According to the media and analysts, “expectations for NextCure and NC 318 [] soar[ed] because … NC318 could become as popular as [Merck’s blockbuster drug] Keytruda if clinical trial results continue to impress.”  On this news, NextCure’s stock closed at $92.22 per share, up nearly 250% from the previous day’s close.

On November 19, 2019, NextCure closed its SPO, raising $172.2 million in gross proceeds.  The offering documents touted the efficacy and effectiveness of NC318.

Then, on July 13, 2020, NextCure announced the departure of its Chief Medical Officer and that it was no longer planning to “advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial.”  On this news, analysts slashed price targets from as high as $87 to as low as $13.  As a result, NextCure’s shares dropped over 54% the next trading day to close at $8.15 per share on July 13, 2020.

If you purchased shares of NextCure (NXTC) between November 5, 2019 and July 14, 2020, you have until November 20, 2020, to ask the court to appoint you lead plaintiff.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns